Product news

Share this article:

Genzyme announced the US launch of phosphate binder Renvela (sevelamer carbonate) for dialysis patients. Renvela is a next-generation version of Renagel (sevelamer hydrochloride). It is a calcium-free, metal-free, non-absorbed phosphate binder and is available in the US as 800 mg tablets.

Onset Therapeutics, a specialty pharmaceutical company that focuses on the development and commercialization of innovative treatments for skin and skin-related disorders, has launched Anestafoam, a novel topical foam formulation containing lidocaine 4%.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.